110 related articles for article (PubMed ID: 3435580)
1. New synthetic approach and iron chelating studies of 1-alkyl-2-methyl-3-hydroxypyrid-4-ones.
Kontoghiorghes GJ; Sheppard L; Chambers S
Arzneimittelforschung; 1987 Oct; 37(10):1099-102. PubMed ID: 3435580
[TBL] [Abstract][Full Text] [Related]
2. Orally active alpha-ketohydroxypyridine iron chelators: studies in mice.
Kontoghiorghes GJ
Mol Pharmacol; 1986 Dec; 30(6):670-3. PubMed ID: 3785144
[TBL] [Abstract][Full Text] [Related]
3. Chelators affecting iron absorption in mice.
Kontoghiorghes GJ
Arzneimittelforschung; 1990 Dec; 40(12):1332-5. PubMed ID: 2095129
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, physicochemical properties, and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones.
Rai BL; Dekhordi LS; Khodr H; Jin Y; Liu Z; Hider RC
J Med Chem; 1998 Aug; 41(18):3347-59. PubMed ID: 9719587
[TBL] [Abstract][Full Text] [Related]
5. Selection of a new generation of orally active alpha-ketohydroxypyridine iron chelators intended for use in the treatment of iron overload.
Kontoghiorghes GJ; Barr J; Nortey P; Sheppard L
Am J Hematol; 1993 Apr; 42(4):340-9. PubMed ID: 8493983
[TBL] [Abstract][Full Text] [Related]
6. Molecular structure and biological and pharmacological properties of 3-hydroxy-2-methyl-1-(beta-D-ribofuranosyl or pyranosyl)-4-pyridinone: potential iron overload drugs for oral administration.
Liu G; Bruenger FW; Miller SC; Arif AM
Bioorg Med Chem Lett; 1998 Nov; 8(21):3077-80. PubMed ID: 9873679
[TBL] [Abstract][Full Text] [Related]
7. Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy.
Devanur LD; Evans RW; Evans PJ; Hider RC
Biochem J; 2008 Jan; 409(2):439-47. PubMed ID: 17919118
[TBL] [Abstract][Full Text] [Related]
8. Effect of novel 1-alkyl-3-hydroxy-2-methylpyrid-4-one chelators on uptake and release of iron from macrophages.
Brock JH; Licéaga J; Arthur HM; Kontoghiorghes GJ
Am J Hematol; 1990 May; 34(1):21-5. PubMed ID: 2327400
[TBL] [Abstract][Full Text] [Related]
9. In vitro characteristics of 1-phenyl-3-methyl-4-acylpyrazol-5-ones iron chelators.
Filipský T; Mladěnka P; Macáková K; Hrdina R; Saso L; Marchetti F; Pettinari C
Biochimie; 2012 Jan; 94(1):125-31. PubMed ID: 21986369
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of iron mobilization from haemosiderin, ferritin and iron(III) precipitates by chelators.
Kontoghiorghes GJ; Chambers S; Hoffbrand AV
Biochem J; 1987 Jan; 241(1):87-92. PubMed ID: 3566714
[TBL] [Abstract][Full Text] [Related]
11. Orally active alpha-ketohydroxypyridine iron chelators: effects on iron and other metal mobilisations.
Kontoghiorghes GJ
Acta Haematol; 1987; 78(2-3):212-6. PubMed ID: 3120474
[TBL] [Abstract][Full Text] [Related]
12. Competition between deferiprone, desferrioxamine and other chelators for iron and the effect of other metals.
Sheppard LN; Kontoghiorghes GJ
Arzneimittelforschung; 1993 Jun; 43(6):659-63. PubMed ID: 8352819
[TBL] [Abstract][Full Text] [Related]
13. Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats.
Kontoghiorghes GJ; Sheppard L; Hoffbrand AV; Charalambous J; Tikerpae J; Pippard MJ
J Clin Pathol; 1987 Apr; 40(4):404-8. PubMed ID: 3584483
[TBL] [Abstract][Full Text] [Related]
14. The study of iron mobilisation from transferrin using alpha-ketohydroxy heteroaromatic chelators.
Kontoghiorghes GJ
Biochim Biophys Acta; 1986 Jan; 869(2):141-6. PubMed ID: 3942757
[TBL] [Abstract][Full Text] [Related]
15. Potential role of in vitro iron bioavailability studies in combatting iron deficiency: a study of the effects of phosvitin on iron mobilization from pinto beans.
Reddy MB; Chidambaram MV; Fonseca J; Bates GW
Clin Physiol Biochem; 1986; 4(1):78-86. PubMed ID: 3006970
[TBL] [Abstract][Full Text] [Related]
16. Iron binding dendrimers: a novel approach for the treatment of haemochromatosis.
Zhou T; Neubert H; Liu DY; Liu ZD; Ma YM; Kong XL; Luo W; Mark S; Hider RC
J Med Chem; 2006 Jul; 49(14):4171-82. PubMed ID: 16821777
[TBL] [Abstract][Full Text] [Related]
17. [Current possibilities in the therapy of iron overload].
Cermák J
Vnitr Lek; 1994 Sep; 40(9):605-8. PubMed ID: 7975366
[TBL] [Abstract][Full Text] [Related]
18. The iron chelators desferrioxamine and 1-alkyl-2-methyl-3-hydroxypyrid-4-ones inhibit vascular prostacyclin synthesis in vitro.
Jeremy JY; Kontoghiorghes GJ; Hoffbrand AV; Dandona P
Biochem J; 1988 Aug; 254(1):239-44. PubMed ID: 3140797
[TBL] [Abstract][Full Text] [Related]
19. Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity.
Chaston TB; Richardson DR
Am J Hematol; 2003 Jul; 73(3):200-10. PubMed ID: 12827659
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and in vitro trypanocidal activity of some novel iron chelating agents.
Singh PK; Jones MM; Lane JE; Nesset A; Zimmerman LJ; Ribeiro-Rodrigues R; Richter A; Stenger MR; Carter CE
Arzneimittelforschung; 1997 Mar; 47(3):311-5. PubMed ID: 9105552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
